{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:07:19Z","timestamp":1789031239475,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T00:00:00Z","timestamp":1616976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000015","name":"Canadian Cancer Society Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jconrel.2021.03.042","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T17:56:36Z","timestamp":1617126996000},"page":"246-257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Development and characterization of a novel flavopiridol formulation for treatment of acute myeloid leukemia"],"prefix":"10.1016","volume":"333","author":[{"given":"Kent T.J.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gardenia G.C.","family":"Militao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malathi","family":"Anantha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Witzigmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada W.Y.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel B.","family":"Bally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9550","key":"10.1016\/j.jconrel.2021.03.042_bb0005","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(06)69780-8","article-title":"Acute myeloid leukaemia","volume":"368","author":"Estey","year":"2006","journal-title":"Lancet."},{"issue":"14","key":"10.1016\/j.jconrel.2021.03.042_bb0010","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJM199909303411407","article-title":"Acute myeloid leukemia","volume":"341","author":"Lowenberg","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.jconrel.2021.03.042_bb0015","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.beha.2018.09.005","article-title":"Is the overall survival for older adults with AML finally improving?","volume":"31","author":"Lancet","year":"2018","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"2","key":"10.1016\/j.jconrel.2021.03.042_bb0020","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/j.seminhematol.2019.02.002","article-title":"Shifting paradigms in the treatment of older adults with AML","volume":"56","author":"LeBlanc","year":"2019","journal-title":"Semin. Hematol."},{"issue":"2","key":"10.1016\/j.jconrel.2021.03.042_bb0025","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/1947601911408076","article-title":"Genetic abnormalities and challenges in the treatment of acute myeloid leukemia","volume":"2","author":"Kumar","year":"2011","journal-title":"Genes Cancer"},{"issue":"3","key":"10.1016\/j.jconrel.2021.03.042_bb0030","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1634\/theoncologist.2008-0224","article-title":"Acute myelogenous leukemia in older adults","volume":"14","author":"Klepin","year":"2009","journal-title":"Oncologist"},{"issue":"9865","key":"10.1016\/j.jconrel.2021.03.042_bb0035","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0140-6736(12)61727-9","article-title":"Acute myeloid leukaemia in adults","volume":"381","author":"Ferrara","year":"2013","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jconrel.2021.03.042_bb0040","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1200\/JCO.2010.30.5961","article-title":"First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia","volume":"29","author":"Feldman","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.jconrel.2021.03.042_bb0045","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood-2017-08-784066","article-title":"Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML","volume":"130","author":"Wei","year":"2017","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.jconrel.2021.03.042_bb0050","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11095-019-2654-z","article-title":"Recent treatment advances and the role of nanotechnology, combination products, and immunotherapy in changing the therapeutic landscape of acute myeloid leukemia","volume":"36","author":"Chen","year":"2019","journal-title":"Pharm. Res."},{"issue":"6","key":"10.1016\/j.jconrel.2021.03.042_bb0055","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0145-2126(02)00265-5","article-title":"Flavonoid effects on normal and leukemic cells","volume":"27","author":"Liesveld","year":"2003","journal-title":"Leuk. Res."},{"issue":"7","key":"10.1016\/j.jconrel.2021.03.042_bb0060","first-page":"2482","article-title":"Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts","volume":"91","author":"Arguello","year":"1998","journal-title":"Blood."},{"key":"10.1016\/j.jconrel.2021.03.042_bb0065","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0040-4039(01)93556-7","article-title":"Structure of rohitukine, the main alkaloid of Amoora-Rohituka (Syn Aphanamixis-Polystachya) (Meliaceae)","volume":"8","author":"Harmon","year":"1979","journal-title":"Tetrahedron Lett."},{"issue":"7","key":"10.1016\/j.jconrel.2021.03.042_bb0070","first-page":"2081","article-title":"An antiinflammatory cum immunomodulatory piperidinylbenzopyranone from dysoxylum-binectariferum - isolation","volume":"44","author":"Naik","year":"1988","journal-title":"Struct. Total Synthesis Tetrahedron."},{"issue":"6B","key":"10.1016\/j.jconrel.2021.03.042_bb0075","first-page":"4341","article-title":"Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo","volume":"25","author":"Wirger","year":"2005","journal-title":"Anticancer Res."},{"issue":"7","key":"10.1016\/j.jconrel.2021.03.042_bb0080","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/leu.2014.40","article-title":"Efficacy of cyclin-dependent-kinase 9 inhibitors in a murine model of mixed-lineage leukemia","volume":"28","author":"Garcia-Cuellar","year":"2014","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.jconrel.2021.03.042_bb0085","first-page":"2973","article-title":"Flavopiridol induces G(1) arrest with inhibition of cyclin-dependent kinase (CDK)2 and CDK4 in human breast carcinoma cells","volume":"56","author":"Carlson","year":"1996","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.jconrel.2021.03.042_bb0090","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/pbc.21386","article-title":"Flavopiridol displays preclinical activity in acute lymphoblastic leukemia","volume":"50","author":"Jackman","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"issue":"2","key":"10.1016\/j.jconrel.2021.03.042_bb0095","first-page":"273","article-title":"Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells","volume":"3","author":"Drees","year":"1997","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.jconrel.2021.03.042_bb0100","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1517\/13543784.9.12.2903","article-title":"Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status","volume":"9","author":"Kelland","year":"2000","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"2","key":"10.1016\/j.jconrel.2021.03.042_bb0105","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1006\/bbrc.1994.1742","article-title":"Potent inhibition of Cdc2 kinase-activity by the flavonoid L86-8275","volume":"201","author":"Losiewicz","year":"1994","journal-title":"Biochem. Bioph. Res. Co."},{"issue":"7","key":"10.1016\/j.jconrel.2021.03.042_bb0110","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1073\/pnas.93.7.2735","article-title":"Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase","volume":"93","author":"de Azevedo","year":"1996","journal-title":"P. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.jconrel.2021.03.042_bb0115","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1006\/abbi.2000.2220","article-title":"The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase","volume":"386","author":"Kaiser","year":"2001","journal-title":"Arch. Biochem. Biophys."},{"issue":"7","key":"10.1016\/j.jconrel.2021.03.042_bb0120","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrd2907","article-title":"Cell cycle kinases as therapeutic targets for cancer","volume":"8","author":"Lapenna","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6518","key":"10.1016\/j.jconrel.2021.03.042_bb0125","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/374131a0","article-title":"Principles of Cdk regulation","volume":"374","author":"Morgan","year":"1995","journal-title":"Nature."},{"issue":"8","key":"10.1016\/j.jconrel.2021.03.042_bb0130","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1200\/JCO.2002.08.080","article-title":"Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors","volume":"20","author":"Schwartz","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.jconrel.2021.03.042_bb0135","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.4161\/cc.3.12.1278","article-title":"Flavopiridol, an inhibitor of transcription - implications, problems and solutions","volume":"3","author":"Blagosklonny","year":"2004","journal-title":"Cell Cycle"},{"issue":"10","key":"10.1016\/j.jconrel.2021.03.042_bb0140","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1182\/blood.V92.10.3804","article-title":"Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53","volume":"92","author":"Byrd","year":"1998","journal-title":"Blood."},{"issue":"7","key":"10.1016\/j.jconrel.2021.03.042_bb0145","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1182\/blood-2005-04-1678","article-title":"Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death","volume":"106","author":"Chen","year":"2005","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.jconrel.2021.03.042_bb0150","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1023\/A:1006353008903","article-title":"Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials","volume":"17","author":"Senderowicz","year":"1999","journal-title":"Investig. New Drugs"},{"issue":"9","key":"10.1016\/j.jconrel.2021.03.042_bb0155","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1200\/JCO.1998.16.9.2986","article-title":"Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms","volume":"16","author":"Senderowicz","year":"1998","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.jconrel.2021.03.042_bb0160","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/annonc\/mdg343","article-title":"Phase II study of flavopiridol in patients with advanced colorectal cancer","volume":"14","author":"Aklilu","year":"2003","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.jconrel.2021.03.042_bb0165","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1023\/B:DRUG.0000026258.02846.1c","article-title":"Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma","volume":"22","author":"Burdette-Radoux","year":"2004","journal-title":"Investig. New Drugs"},{"issue":"6","key":"10.1016\/j.jconrel.2021.03.042_bb0170","first-page":"1590","article-title":"A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer","volume":"7","author":"Shapiro","year":"2001","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.jconrel.2021.03.042_bb0175","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.leukres.2005.03.010","article-title":"Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity","volume":"29","author":"Flinn","year":"2005","journal-title":"Leuk. Res."},{"issue":"9","key":"10.1016\/j.jconrel.2021.03.042_bb0180","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/leu.2011.109","article-title":"Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol","volume":"25","author":"Blum","year":"2011","journal-title":"Leukemia."},{"issue":"5","key":"10.1016\/j.jconrel.2021.03.042_bb0185","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1158\/1078-0432.CCR-12-1092","article-title":"A pharmacokinetic\/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol","volume":"19","author":"Ji","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2021.03.042_bb0190","first-page":"294b","article-title":"Flavopiridol sensitivity of chronic lymphocytic leukemia (CLL) cells in vitro varies based upon species specific drug protein binding","volume":"96","author":"Shinn","year":"2000","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jconrel.2021.03.042_bb0195","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1021\/js990097r","article-title":"Solubilization of flavopiridol by pH control combined with cosolvents, surfactants, or complexants","volume":"88","author":"Li","year":"1999","journal-title":"J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.jconrel.2021.03.042_bb0200","first-page":"356","article-title":"Parenteral formulation of flavopiridol (NSC-649890)","volume":"50","author":"Dannenfelser","year":"1996","journal-title":"PDA J. Pharm. Sci. Technol."},{"issue":"1","key":"10.1016\/j.jconrel.2021.03.042_bb0205","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.jconrel.2021.03.042_bb0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153416","article-title":"Nanoscale reaction vessels designed for synthesis of copper-drug complexes suitable for preclinical development","volume":"11","author":"Wehbe","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2021.03.042_bb0215","series-title":"Fundamentals of Pharmaceutical Nanoscience","first-page":"27","article-title":"Liposomes","author":"Kalra","year":"2013"},{"key":"10.1016\/j.jconrel.2021.03.042_bb0220","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jconrel.2017.08.023","article-title":"Zebrafish as an early stage screening tool to study the systemic circulation of nanoparticulate drug delivery systems in vivo","volume":"264","author":"Sieber","year":"2017","journal-title":"J. Control. Release"},{"issue":"91","key":"10.1016\/j.jconrel.2021.03.042_bb0225","doi-asserted-by":"crossref","first-page":"74320","DOI":"10.1039\/C5RA13967H","article-title":"Formation of lipid and polymer based gold nanohybrids using a nanoreactor approach","volume":"5","author":"Witzigmann","year":"2015","journal-title":"RSC Adv."},{"issue":"18","key":"10.1016\/j.jconrel.2021.03.042_bb0230","doi-asserted-by":"crossref","first-page":"9023","DOI":"10.1039\/C9NR02004G","article-title":"Fusion-dependent formation of lipid nanoparticles containing macromolecular payloads","volume":"11","author":"Kulkarni","year":"2019","journal-title":"Nanoscale."},{"issue":"3","key":"10.1016\/j.jconrel.2021.03.042_bb0235","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ejpb.2007.08.011","article-title":"A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention","volume":"68","author":"Ramsay","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"4","key":"10.1016\/j.jconrel.2021.03.042_bb0240","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/bjc.1995.430","article-title":"Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models","volume":"72","author":"Webb","year":"1995","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.jconrel.2021.03.042_bb0245","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.bbamem.2006.12.013","article-title":"Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding","volume":"1768","author":"Dos Santos","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"issue":"7","key":"10.1016\/j.jconrel.2021.03.042_bb0250","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3324\/haematol.2009.017103","article-title":"Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias","volume":"95","author":"Blum","year":"2010","journal-title":"Haematologica."},{"issue":"12","key":"10.1016\/j.jconrel.2021.03.042_bb0255","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.leukres.2015.10.010","article-title":"Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia","volume":"39","author":"Zeidner","year":"2015","journal-title":"Leuk. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2021.03.042_bb0260","first-page":"E40","article-title":"The binding of flavopiridol to blood serum albumin","volume":"22","author":"Myatt","year":"2010","journal-title":"Chirality"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2021.03.042_bb0265","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijpharm.2008.08.008","article-title":"A novel liposomal formulation of flavopiridol","volume":"365","author":"Yang","year":"2009","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2021.03.042_bb0270","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(97)00128-2","article-title":"Interactions of liposomes and lipid-based carrier systems with blood proteins: relation to clearance behaviour in vivo","volume":"32","author":"Semple","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.jconrel.2021.03.042_bb0275","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.bbamem.2015.11.012","article-title":"The protein corona of circulating PEGylated liposomes","volume":"1858","author":"Palchetti","year":"2016","journal-title":"Biochim. Biophys. Acta Biomembr."},{"issue":"1","key":"10.1016\/j.jconrel.2021.03.042_bb0280","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0005-2736(98)00168-0","article-title":"Loading of doxorubicin into liposomes by forming Mn2+\u2212drug complexes","volume":"1414","author":"Cheung","year":"1998","journal-title":"Biochim. Biophys. Acta Biomembr."},{"issue":"1","key":"10.1016\/j.jconrel.2021.03.042_bb0285","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0005-2736(02)00507-2","article-title":"Formation of transition metal\u2013doxorubicin complexes inside liposomes","volume":"1565","author":"Abraham","year":"2002","journal-title":"Biochim. Biophys. Acta Biomembr."},{"issue":"9","key":"10.1016\/j.jconrel.2021.03.042_bb0290","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1080\/1061186X.2016.1186169","article-title":"PRCosomes: pretty reactive complexes formed in liposomes","volume":"24","author":"Wehbe","year":"2016","journal-title":"J. Drug Target."},{"issue":"4","key":"10.1016\/j.jconrel.2021.03.042_bb0295","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3390\/jcm4040665","article-title":"Current approaches in the treatment of relapsed and refractory acute myeloid leukemia","volume":"4","author":"Ramos","year":"2015","journal-title":"J. Clin. Med."},{"issue":"9","key":"10.1016\/j.jconrel.2021.03.042_bb0300","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3324\/haematol.2015.134023","article-title":"The FLAM regimen: revisiting time sequential induction therapy for patients with poor-risk acute myeloid leukemia","volume":"100","author":"Knapper","year":"2015","journal-title":"Haematologica."},{"key":"10.1016\/j.jconrel.2021.03.042_bb0305","first-page":"125849","article-title":"Randomized multicenter phase 2 study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine\/daunorubicin (7+ 3) in newly diagnosed acute myeloid leukemia","author":"Zeidner","year":"2015","journal-title":"Haematologica"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592100153X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592100153X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:57:38Z","timestamp":1759161458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836592100153X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":61,"alternative-id":["S016836592100153X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.03.042","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and characterization of a novel flavopiridol formulation for treatment of acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.03.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}